Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HOWL | 144 | bearish | 5/10 | Three affiliated MPM entities, MPM Asset Management LLC, MPM Oncology Innovations Fund LP, and MPM BioVentures 2014, L.P | May 1, 2026 |
| SNTI | 424B5 | bearish | 6/10 | Senti Biosciences filed a 424B5 prospectus supplement for its existing at-the-market (ATM) equity offering program, upda | May 1, 2026 |
| PCSA | CLUSTER | bullish | 4/10 | Three C-suite executives at Processa Pharmaceuticals (CEO, CAO, CDO) purchased a combined ~$15.5K of stock on April 30, | May 1, 2026 |
| MANE | 8-K | neutral | 5/10 | Veradermics closed an underwritten public offering of 3,843,790 shares at $100.00 per share, raising ~$384M, and a concu | May 1, 2026 |
| KNSA | 8-K | neutral | 2/10 | Chief Strategy Officer Eben Tessari resigned effective May 15, 2026 to pursue another executive position in life science | May 1, 2026 |
| BRNS | 3 | neutral | 2/10 | Douglas J. Swirsky filed a Form 3 initial statement of beneficial ownership as the new Principal Accounting Officer of B | May 1, 2026 |
| ORGNW | 8-K | bearish | 9/10 | Origin Materials announced a plan of complete liquidation and dissolution, subject to stockholder approval, and implemen | May 1, 2026 |
| CNTX | 8-K | neutral | 2/10 | Context Therapeutics resolved a stockholder class action lawsuit challenging its charter provisions. Under a court-appro | May 1, 2026 |
| CRIS | 8-K | bearish | 8/10 | Curis received a Nasdaq delisting determination letter on April 27, 2026, because its common stock bid price closed belo | May 1, 2026 |
| ESPR | DEFA14A | bullish | 7/10 | Esperion Therapeutics entered into a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, plus c | May 1, 2026 |
| PRRUF | 6-K | bearish | 8/10 | Immutep reported discontinuation of its lead TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small cell | May 1, 2026 |
| JAZZ | 144 | neutral | 2/10 | Bruce C. Cozadd, an officer at Jazz Pharmaceuticals, filed a Form 144 indicating intent to sell 6,000 shares of common s | May 1, 2026 |
| MBX | 144 | bearish | 5/10 | Former officer Richard Bartram files Form 144 to sell 5,000 MBX shares (~$159k), adding to 21,484 shares already sold in | May 1, 2026 |
| ARVN | 8-K | bullish | 8/10 | Arvinas announced FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced breast cancer, the first- | May 1, 2026 |
| ARVN | PRESS-RELEASE | bullish | 8/10 | Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-muta | May 1, 2026 |
| PDSB | 8-K | bearish | 6/10 | PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity) and issued a warran | May 1, 2026 |
| RZLT | PRESS-RELEASE | mixed | 5/10 | Rezolute released expanded Phase 3 sunRIZE study data showing clinically meaningful glycemic improvements on multiple CG | May 1, 2026 |
| MEOH | 6-K | neutral | 2/10 | Methanex filed its 6-K reporting the results of its Annual General Meeting held on April 30, 2026. All director nominees | May 1, 2026 |
| HYPD | PRESS-RELEASE | neutral | 1/10 | Hyperion DeFi, Inc. announced it will host a conference call on May 14 to discuss its Q1 results. | May 1, 2026 |
| GLAXF | 6-K | neutral | 1/10 | GSK plc disclosed its total voting rights as of 30 April 2026, reporting 4,316,202,660 issued shares, 261,378,286 in tre | May 1, 2026 |
| GLAXF | 6-K | neutral | 3/10 | Dodge & Co filed a TR-1 notification disclosing a 4.93% voting rights stake in GSK plc as of April 28, 2026, crossing th | May 1, 2026 |
| AZN | 6-K | neutral | 2/10 | AstraZeneca filed a routine 6-K reporting total voting rights as of April 30, 2026 (1,550,995,630 shares) and the admiss | May 1, 2026 |
| BFRGW | DEFA14A | neutral | 2/10 | BullFrog AI Holdings, Inc. filed a DEFA14A (definitive additional proxy soliciting materials) on May 1, 2026. The filing | May 1, 2026 |
| SHPH | 8-K | bearish | 7/10 | Shuttle Pharmaceuticals entered into a merger agreement with United Dogecoin Inc., a dogecoin mining company, and concur | May 1, 2026 |
| VXRT | PRESS-RELEASE | bearish | 7/10 | Vaxart reported a significant Q4 2025 EPS miss of -$0.10 versus the $0.02 consensus, a 600% negative surprise. No revenu | May 1, 2026 |
| AMTX | PRESS-RELEASE | neutral | 1/10 | Aemetis, Inc. announced it will report its Q1 2026 results on May 7, 2026. | May 1, 2026 |
| PHAT | PRESS-RELEASE | neutral | 1/10 | Phathom Pharmaceuticals announced its participation in the Digestive Disease Week (DDW) 2026 annual meeting, including a | May 1, 2026 |
| IFRX | PRESS-RELEASE | neutral | 1/10 | InflaRx N.V. announced it will report its Q1 2026 results on May 7, 2026. | May 1, 2026 |
| AXSM | PRESS-RELEASE | bullish | 8/10 | Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's disease dementia, a maj | May 1, 2026 |
| ESPR | PRESS-RELEASE | bullish | 7/10 | Esperion has agreed to be acquired by ARCHIMED for $3.16 per share in cash at closing, plus contingent milestone payment | May 1, 2026 |